Evidence map›Paper›PMID 19727388›Full record

ArticlePloS one2009

Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis.

Karen L Wozniak, Sailatha Ravi, Sandra Macias, Mattie L Young, Michal A Olszewski, Chad Steele, Floyd L Wormley

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 98 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Lack of an atypical PDR transporter generates an immunogenicbioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Dendritic Cells: Multifunctional Roles in Host Defenses toJournal of fungi (Basel, Switzerland) · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Hemolymph of triatomines presents fungistatic activity againstThe journal of venomous animals and toxins including tropical diseases · 2022
    Article
  20. Frontiers in immunology · 2022
    Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Karen L WozniakDepartment of Biology, The University of Texas at San Antonio, San Antonio, Texas, United States of America.
Sailatha Ravi
Sandra Macias
Mattie L Young
Michal A Olszewski
Chad Steele
Floyd L Wormley
Texas Center for Infectious Disease · USThe University of Texas at San Antonio · USUniversity of Alabama at Birmingham · USVA Ann Arbor Healthcare System · US

Funding

Protective Host Immunity Against Pulmonary CryptococcosisR01AI071752 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI WORMLEY, FLOYD L. · 2007 to 2018
$3.7M
Dectin-1 and Immunity Against Pneumocystis CariniiR01HL080317 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STEELE, CHAD · 2005 to 2009
$1.6M
NHLBI NIH HHS HL080317NHLBI NIH HHS R01 HL080317NIAID NIH HHS R01 AI071752NIAID NIH HHS R01 AI071752-03
6 · The paper itself

Abstract

Cryptococcus neoformans is an opportunistic fungal pathogen that causes life-threatening pneumonia and meningoencephalitis in immune compromised individuals. Previous studies have shown that immunization of BALB/c mice with an IFN-gamma-producing C. neoformans strain, H99gamma, results in complete protection against a second pulmonary challenge with an otherwise lethal cryptococcal strain. The current study evaluated local anamnestic cell-mediated immune responses against pulmonary cryptococcosis in mice immunized with C. neoformans strain H99gamma compared to mice immunized with heat-killed C. neoformans (HKC.n.). Mice immunized with C. neoformans strain H99gamma had significantly reduced pulmonary fungal burden post-secondary challenge compared to mice immunized with HKC.n. Protection against pulmonary cryptococcosis was associated with increased pulmonary granulomatous formation and leukocyte infiltration followed by a rapid resolution of pulmonary inflammation, which protected the lungs from severe allergic bronchopulmonary mycosis (ABPM)-pathology that developed in the lungs of mice immunized with HKC.n. Pulmonary challenge of interleukin (IL)-4 receptor, IL-12p40, IL-12p35, IFN-gamma, T cell and B cell deficient mice with C. neoformans strain H99gamma demonstrated a requirement for Th1-type T cell-mediated immunity, but not B cell-mediated immunity, for the induction of H99gamma-mediated protective immune responses against pulmonary C. neoformans infection. CD4(+) T cells, CD11c(+) cells, and Gr-1(+) cells were increased in both proportion and absolute number in protected mice. In addition, significantly increased production of Th1-type/pro-inflammatory cytokines and chemokines, and conversely, reduced Th2-type cytokine production was observed in the lungs of protected mice. Interestingly, protection was not associated with increased production of cytokines IFN-gamma or TNF-alpha in lungs of protected mice. In conclusion, immunization with C. neoformans strain H99gamma results in the development of protective anti-cryptococcal immune responses that may be measured and subsequently used in the development of immune-based therapies to combat pulmonary cryptococcosis.

Indexed as

AnimalsAntibodies, FungalCryptococcosisCryptococcus neoformansCytokinesDisease Models, AnimalFemaleImmunity, CellularLeukocytesLungLung Diseases, FungalMiceMice, Inbred BALB CTh1 CellsT-LymphocytesAntibodies, FungalCytokines

Identifiers

PMID19727388
PMCPMC2731172
OpenAlexW2076677132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.